Novartis: Schizophrenia trials
The registry lists 10 Schizophrenia studies with Novartis as lead sponsor. 2 are open to participants now and 3 have results posted.
Phase 1 3Phase 2 7Phase 3 1Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable SchizophreniaRecruitingNCT07908680Phase 1
- Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With SchizophreniaRecruitingNCT07467993Phase 2
- Study of Efficacy of PEAR-004 in SchizophreniaCompletedNCT03751280Phase 2Results posted
- Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic PatientsCompletedNCT01348100Phase 1/2Results posted
- Switching to Iloperidone From Other Antipsychotics in SchizophreniaCompletedNCT01207414Phase 4Results posted
- A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia PatientsCompletedNCT01730768Phase 2
- Effect of AQW051 on Cognitive Function in Patients With Chronic Stable SchizophreniaCompletedNCT01163227Phase 2
- Pharmacodynamic/Pharmacokinetic Study of AQW051 in SchizophreniaCompletedNCT00825539Phase 1/2
- A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant SchizophreniaCompletedNCT00250575Phase 3
- A Long Term Study of Clozapine in Patients With Treatment-resistant SchizophreniaCompletedNCT00154258Phase 2